Navigation Links
Results From Phase 3 CAPACITY Program of Pirfenidone in IPF and Study of Predictors of Mortality in IPF to be Presented at ATS
Date:5/14/2009

ess release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements. Pirfenidone failed to achieve statistical significance on the primary endpoint in one of its two pivotal clinical trials and there can be no assurance that the regulatory authorities in either the United States or Europe will grant regulatory approval based upon these data, in combination with the other efficacy and safety results the company currently intends to submit in support of its NDA and MAA filings. Further analyses of the CAPACITY results will be conducted in the future and additional observations may be made which may lead to material change in the company's current regulatory strategy for pirfenidone, including a decision by the company not to proceed with either or both of its regulatory submissions in the United States and Europe. These analyses and observations will be included in one or more scientific publications. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the SEC on March 16, 2009 (the "Form 10-K") and other periodic reports filed with the SEC, including the following: (i) risks related to the long, expensive and uncertain clinical development and regulatory process, including having no unexpected safety, toxicology, clinical or other issues or delays in anticipated timing of the regulatory approval process; (ii) risks related to failure to achieve the clinical trial results required to commercialize our product candidates; and (iii) risks related to timely patient enrollment and retention in clinical trials. The risks and other factors discussed above should be considered on
'/>"/>
SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Oncothyreon reports first quarter 2009 financial results
2. YM BIOSCIENCES REPORTS THIRD QUARTER 2009 OPERATIONAL AND FINANCIAL RESULTS
3. Transgenomic, Inc. Reports First Quarter 2009 Results
4. Insmed Announces First Quarter 2009 Financial Results
5. BioMS Medical Announces First quarter 2009 results
6. Pharmasset Reports Fiscal Second Quarter 2009 Financial Results
7. China Sky One Medical, Inc. Schedules Conference Call to Discuss First Quarter 2009 Results
8. deCODE genetics Announces First Quarter 2009 Financial Results
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2009 Financial Results on Thursday, May 14, 2009 at 8:30am EDT
10. Arena Pharmaceuticals Announces First Quarter 2009 Financial Results
11. VIVUS Reports First Quarter 2009 Financial Results and Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... Psyche Systems Corporation and Luminate Health have ... platform that helps labs comply with new federal HHS ... way patients engage with these results, and improves provider ... a HIPAA-compliant digital platform that gives labs an easy ... lab results, and uniquely connects labs, physicians, and patients ...
(Date:5/5/2015)... NEW YORK , May 5, 2015 /PRNewswire/ ... today announced that Andrew Gengos , President and ... on May 7, 2015. DATE:  Thursday, May ... LINK:  http://VirtualInvestorConferences.com > click the ... will be a live, interactive online event where ...
(Date:5/5/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/4r95kr/clinical ) ... Laboratory, Molecular Diagnostics and Genomic Testing Services Market ... Version" report to their offering. ... molecular diagnostics and pharmacogenics hold the promise of ... is moving out of the national and regional ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 GEA ... last week as recipients of the INTERPHEX Exhibitor ... recognition of their Portable, Continuous, Miniature and Modular ... a small footprint, continuous processing equipment, smart control ... process API powders and inactive ingredients into bulk ...
Breaking Biology Technology:Psyche Systems Corporation Forms Strategic Alliance with Luminate Health to Provide First-of-its-kind Patient Access Solution 2Psyche Systems Corporation Forms Strategic Alliance with Luminate Health to Provide First-of-its-kind Patient Access Solution 3ImmunoCellular Therapeutics to Webcast Live at VirtualInvestorConferences.com on May 7 2European Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market 2015-2019 2GEA Pharma Systems, G-CON Manufacturing and Pfizer Consortium Receives Best Technology Innovation Award at INTERPHEX 2015 2GEA Pharma Systems, G-CON Manufacturing and Pfizer Consortium Receives Best Technology Innovation Award at INTERPHEX 2015 3
... 29 SCOLR Pharma, Inc.,(Amex: DDD ) today ... Thursday, August 7, 2008, at 8:30 a.m. Eastern. Daniel ... a conference call at 11:30,a.m. Eastern, to discuss the ... in the,conference call by dialing +1 888 680 0878 ...
... to Attract a Record Number of ... ... the world,s,leading online medical device and diagnostics job board and career ... September 8, 2008. The event will take place at the Minneapolis,Airport ...
... Ill., July 29 The Board of,Directors of Baxter ... dividend of $0.2175 per share of Baxter common stock., ... rate, which was,increased earlier this year by 30 percent. ... shareholders of record as of September 10,2008., Baxter ...
Cached Biology Technology:SCOLR Pharma, Inc. Schedules Second Quarter 2008 Financial Results Conference Call for August 7, 2008 at 11:30 A.M. Eastern 2DeviceSpace(TM) to Host Medical Device and Diagnostics Career Fair in Minneapolis 2
(Date:3/24/2015)... --  NexID Biometrics LLC, whose spoof-mitigation technology boosts ... the beginning of shipments of version 2.0 of its ... based in Potsdam, N.Y. , is ... began here today at the Walter E. Washington Convention ... SDK boosts the accuracy rate range to 96.5 to ...
(Date:3/23/2015)... -- In the 2014 fiscal year, irs.gov recorded over $100 ... accounts for a fraction of the estimated losses for ... $11 billion globally. The polygraph has traditionally been used ... Investor Mark Saint Juste along with former ... partnered to administer the test in a new way: ...
(Date:3/20/2015)... March 20, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces ... one of the products featured in 2015 "I Want ... 11:00 PM EST on the DIY Network.   ... Las Vegas , site of the 2015 International ...
Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3
... team of biomedical researchers from the USC Viterbi School, the ... received a $6-million Bioengineering Research Partnership grant from the National ... millions of older adults who suffer from significant vision loss. ... led by Norberto Grzywacz, professor of biomedical engineering in the ...
... of Molecular & Cellular Proteomics (Vol. 6, No. 10): ... in the brain , Improving cancer diagnosis , ... Preventing neurodegenerative diseases by studying proteins in the brain ... present in the cerebral cortex the outermost layer of the ...
... National Institute of Biomedical Imaging and Bioengineering (NIBIB), ... today announced the award of more than $12 ... of potentially high-impact, innovative technologies to advance health ... four investigators in developing groundbreaking technologies: disposable ...
Cached Biology News:USC biomedical team to participate in $6 million low vision project 2USC biomedical team to participate in $6 million low vision project 3USC biomedical team to participate in $6 million low vision project 4Story ideas from Molecular & Cellular Proteomics 2Story ideas from Molecular & Cellular Proteomics 3Story ideas from Molecular & Cellular Proteomics 4NIBIB invests in quantum research 2NIBIB invests in quantum research 3
100 ug affinity purified rabbit anti-JIP-1 polyclonal antibody. Reacts with mouse and rat. Perform well in Western blotting. Other applications have not been tested. Storage Temperature: -20C Shi...
Melanoma Antigen, Family C, 1 (MAGEC1) Rabbit anti-Human Polyclonal Antibody Immunogen: Synthetic peptide - KLH conjugated Family: New Recommended Storage: Long term: -20C; Short term: +4...
X box-binding protein 1...
Mouse monoclonal [AE3] to Cytokeratin 1 - 8, prediluted ( Abpromise for all tested applications). Antigen: Tissue / cell preparation - Human epidermal cells. Entrez GeneID: 140807 Swiss P...
Biology Products: